Deep Medicine Acquisition Corp. Rights
DMAQR
DMAQR was delisted on the 31st of January, 2024.
28 hedge funds and large institutions have $1.73M invested in Deep Medicine Acquisition Corp. Rights in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.
15% less funds holding
Funds holding: 33 → 28 (-5)
46% less capital invested
Capital invested by funds: $3.2M → $1.73M (-$1.47M)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAC
Cowen and Company
New York
|
+$144K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$177 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Oaktree Capital Management
Los Angeles,
California
|
-$136K |
| 2 |
CCM
Context Capital Management
Lajolla,
California
|
-$63K |
| 3 |
D.E. Shaw & Co
New York
|
-$46.3K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$12.6K |
| 5 |
SCM
Saba Capital Management
New York
|
-$9.99K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
26
Bluefin Capital Management
New York
| $3K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $2K | – | – | – |
|
|
28
UBS Group
Zurich,
Switzerland
| $1K | +$177 | +700 | +30% |
|
|
OCM
29
Oaktree Capital Management
Los Angeles,
California
| – | -$136K | -425,000 | Closed |
|
|
CCM
30
Context Capital Management
Lajolla,
California
| – | -$63K | -198,000 | Closed |
|
31
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$5K | -15,124 | Closed |
|
32
Jane Street
New York
| – | -$4K | -11,818 | Closed |
|
|
AA
33
Ancora Advisors
Cleveland,
Ohio
| – | -$2K | -5,000 | Closed |
|
DMAQR Hedge Fund Activity: Q1 2022 in Review
28 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Deep Medicine Acquisition Corp. Rights (DMAQR) for Q1 2022, worth a combined $1.73M — down 46% from $3.2M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of DMAQR and 0 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Cowen and Company, adding an estimated $144K. The largest seller was Oaktree Capital Management, exiting entirely with an estimated $136K sold.
- 28 institutional investors held Deep Medicine Acquisition Corp. Rights (DMAQR) as of Q1 2022, down from 33 in Q4 2021.
- Funds reported $1.73M of Deep Medicine Acquisition Corp. Rights stock for Q1 2022, down 46% quarter-over-quarter.
- 0 funds opened new Deep Medicine Acquisition Corp. Rights positions in Q1 2022 and 5 closed out, a net change of -5 holders.
- The largest Deep Medicine Acquisition Corp. Rights buyer in Q1 2022 was Cowen and Company, an estimated $144K added.
- The largest Deep Medicine Acquisition Corp. Rights seller in Q1 2022 was Oaktree Capital Management, an estimated $136K sold.
Based on aggregated 13F filings for Q1 2022.